Optina Diagnostics Inc., a Montreal, Canada-based provider of an early detection of Alzheimer through the use of Artificial Intelligence (AI) and Spectral Retinal Imaging, raised C$4m in funding.
The round was led by Zoic Capital with participation from Desjardins Capital, DigitalDx Ventures, Pallasite Ventures, Barney Pell, Barney Pell’s AngelList Syndicate, Advisors.fund and Hike Ventures.
The company intends to use the funds to scale up its clinical development and accelerate its growth and market readiness.
Led by David Lapointe, CEO, Optina Diagnostics focuses on the development of technology for the early detection of disease through hyperspectral imaging of the eye. Given clinical data gathered through the financial support of CQDM and CTS, the company is ready to extend its clinical sites and focus on the regulatory approval of it’s cerebral Amyloid prediction test.
The first application will be in the early diagnosis of Alzheimer’s.